ESPR Stock Analysis: Buy, Sell, or Hold?

ESPR - Esperion Therapeutics, Inc.

PHARMACEUTICAL PREPARATIONS
$3.13
0.00 (0.00%) ▲
5d: +0.32%
30d: +63.02%
90d: -11.08%
BUY
MODERATE Confidence
Protect Your ESPR Gains
Analysis Updated: May 20, 2026 12:00 AM ET
Earnings: May 12, 2026 0d

Get Alerted When ESPR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: ESPR shows positive signals but monitor for confirmation. Market pricing in 38.8% decline. Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$10.23
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.35
50.7% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ESPR is currently trading at $3.13, which is considered slightly high relative to its 30-day fair value range of $2.00 to $3.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.7) compared to its historical average (46.9). Remarkably, the market is currently pricing in an annual earnings decline of 38.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.11. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: ESPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $2.00 - $3.13
Company Quality Score 60/100 (BUY)
Volume Confirmation HIGH
Confidence Score 71.4%

Protect Your Profits

ESPR is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($3.19)

Trading Range Analysis

30-Day Trading Range $2.00 - $3.13
Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $3.11
Resistance Level $3.15
Current Trend Strong Uptrend
Technical data as of May 20, 2026

Fundamental Context

Forward P/E (Next Year Est.) 10.72
Wall Street Target $3.19 (+1.9%)
Revenue Growth (YoY) 23.2%
Profit Margin -1.8%
Valuation Discount vs History -38.8% cheaper
PE vs Historical 10.7 vs 46.9 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -38.8% (market-implied from PE analysis)
1-Year Target $2.82 (-10%)
2-Year Target $2.54 (-19%)
3-Year Target $2.28 (-27%)
3-Yr Target (if PE normalizes) (PE: 11→47) $9.98 (+219%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.7 to 46.9
Stabilization Target: $13.69 (+337.5%)
PE Expansion Potential: +337.5%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: May 21, 2026 12:17 AM ET
Data refreshes hourly during market hours. Next update: 1:17 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Halladay SELL 6424 shares 2026-03-17
Benjamin Looker SELL 5708 shares 2026-03-17
Benjamin Looker SELL 1689 shares 2026-01-20

Unlock Insider Activity

See real-time buying/selling by company executives for ESPR.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
25 analysts
$191 60 HOLD
ZTS
Zoetis Inc
STRONG BUY
19 analysts
$131 56 HOLD
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$104 63 BUY
BCRX
BioCryst Pharmaceuticals…
STRONG BUY
12 analysts
$22 54 HOLD
AVDL
Avadel Pharmaceuticals P…
STRONG BUY
8 analysts
$21 62 BUY

Advanced ESPR Option Strategies

Professional options setups generated by AI based on today's ESPR price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ESPR

ESPR Technical Chart ESPR Price Prediction ESPR Earnings Date ESPR Investment Advisor ESPR Fair Price Analyzer ESPR Options Advisor ESPR Options Chain ESPR Options Analysis ESPR Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals